Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Cancers, 12, 2
- Schlagwort
-
-
- Ereignis
-
Veröffentlichung
- (wo)
-
Greifswald
- (wer)
-
Universität Greifswald
- (wann)
-
2020
- Urheber
-
Ladenstein, Ruth
Pötschger, Ulrike
Valteau-Couanet, Dominique
Luksch, Roberto
Castel, Victoria
Ash, Shifra
Laureys, Geneviève
Brock, Penelope
Michon, Jean Marie
Owens, Cormac
Trahair, Toby
Chi Fung Chan, Godfrey
Ruud, Ellen
Schroeder, Henrik
Beck-Popovic, Maja
Schreier, Guenter
Loibner, Hans
Ambros, Peter
Holmes, Keith
Castellani, Maria Rita
Gaze, Mark N.
Garaventa, Alberto
Pearson, Andrew D.J.
Lode, Holger N.
- DOI
-
10.3390/cancers12020309
- URN
-
urn:nbn:de:gbv:9-opus-35986
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:52 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ladenstein, Ruth
- Pötschger, Ulrike
- Valteau-Couanet, Dominique
- Luksch, Roberto
- Castel, Victoria
- Ash, Shifra
- Laureys, Geneviève
- Brock, Penelope
- Michon, Jean Marie
- Owens, Cormac
- Trahair, Toby
- Chi Fung Chan, Godfrey
- Ruud, Ellen
- Schroeder, Henrik
- Beck-Popovic, Maja
- Schreier, Guenter
- Loibner, Hans
- Ambros, Peter
- Holmes, Keith
- Castellani, Maria Rita
- Gaze, Mark N.
- Garaventa, Alberto
- Pearson, Andrew D.J.
- Lode, Holger N.
- Universität Greifswald
Entstanden
- 2020
Ähnliche Objekte (12)
Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy
Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy
Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR
Understanding and Exploiting MYCN Addiction in High-Risk Neuroblastoma Using the Example of CDK13
Functional validation of novel target structures for treatment of high-risk neuroblastoma
MCM complex as a critical node in the miR-183 signaling network of high-risk neuroblastoma cells
The function of JAGGED1 in neuroblastoma
The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial
Genetic alterations and resectability predict outcome in patients with neuroblastoma assigned to high-risk solely by MYCN amplification
The future of affordable cancer immunotherapy
Immune response and outcome of high-risk neuroblastoma patients immunized with anti-idiotypic antibody ganglidiomab: a compassionate use program
The trial
Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy
Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy
Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR
Understanding and Exploiting MYCN Addiction in High-Risk Neuroblastoma Using the Example of CDK13
Functional validation of novel target structures for treatment of high-risk neuroblastoma
MCM complex as a critical node in the miR-183 signaling network of high-risk neuroblastoma cells
The function of JAGGED1 in neuroblastoma
The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial
Genetic alterations and resectability predict outcome in patients with neuroblastoma assigned to high-risk solely by MYCN amplification
The future of affordable cancer immunotherapy
Immune response and outcome of high-risk neuroblastoma patients immunized with anti-idiotypic antibody ganglidiomab: a compassionate use program
The trial
Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy
Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy
Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR
Understanding and Exploiting MYCN Addiction in High-Risk Neuroblastoma Using the Example of CDK13
Functional validation of novel target structures for treatment of high-risk neuroblastoma
MCM complex as a critical node in the miR-183 signaling network of high-risk neuroblastoma cells
The function of JAGGED1 in neuroblastoma
The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial
Genetic alterations and resectability predict outcome in patients with neuroblastoma assigned to high-risk solely by MYCN amplification
The future of affordable cancer immunotherapy
Immune response and outcome of high-risk neuroblastoma patients immunized with anti-idiotypic antibody ganglidiomab: a compassionate use program